Background: We explore the nature, extent and validity of research studies concerning the management of shoulder arthritis to identify whether current management recommendations are adequate. Methods: A full electronic search for relevant studies published between 2002 and 2012 was performed. The search focused on level 1 and level 2 studies. Full texts of selected articles were retrieved and assessed for quality against validated criteria. Results: Four hundred and eleven studies were identified on the initial search and screened. Sixteen studies were selected for inclusion in the review. The studies identified were unable to provide a clear indication of best intervention for shoulder arthritis. The inclusion of a range of shoulder pathologies in some studies and the diversity in outcome measures used made it difficult for systematic reviews to effectively pool data. Better outcomes have been shown with total shoulder replacement over hemiarthroplasty for shoulder osteoarthritis; however, primary studies were often of limited quality. Sparse evidence is available for all other interventions, regardless of whether operative or non-operative. Conclusions: The present review highlights the need for standardization of outcome assessment following treatment of shoulder arthritis. More rigorous and robust primary studies are needed to guide clinical practice on the best interventions for arthritis of the shoulder.
Introduction
Each year, 1% of the adult population in the UK over the age of 45 years present with new onset shoulder pain. 1 It is the third most common musculoskeletal pain seen in general practice behind back and knee pathologies. 1 Shoulder osteoarthritis is characterized by degeneration of articular cartilage and subchondral bone with narrowing of the glenohumeral joint. It causes significant pain, functional limitation and disability, with an estimated prevalence of between 4% and 26%. 2 Current treatment options for shoulder arthritis are either operative or non-operative. Operative interventions include total shoulder arthroplasty (TSA), hemiarthroplasty, reverse shoulder arthroplasty (RSA) and arthroscopic debridement. Non-operative interventions include physiotherapy, nonsteroidal anti-inflammatory (NSAIDs) medication, intra-articular corticosteroid injections and acupuncture.
In the UK, the provision of TSA and hemiarthroplasty is approximately one-tenth and one-fifth, respectively, per capita compared to the USA, 3 where the number of shoulder arthroplasties, particularly TSA, is growing rapidly. 4 Currently, 47, 000 shoulder replacements are performed annually in North America, of which approximately 27, 000 are TSA. 4 The aim of this scoping review is to critically appraise and summarize the current body of evidence in the management of shoulder arthritis. We aim to explore the nature, extent and validity of research studies carried out in this field and to identify whether current management recommendations are adequate. By mapping a wide range of literature, we aim to identify where gaps and innovative approaches may lie.
Materials and Methods
For the purpose of this scoping review, the six-stage methodological framework developed by Arksey This report covers the first five stages of the framework, providing the template for consultation with stakeholders.
Literature search
Evidence was gathered from NHS Evidence, National Guideline Clearing House, Centre for Reviews and Dissemination Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Medline and Embase from 2002 to 2012 using relevant controlled vocabulary terms and key terms related to shoulder arthritis and its treatments. The search focused on level 1 and level 2 randomized controlled trials (RCTs) and systematic reviews. The gathered literature was limited to publications in English. The only exclusion criterion used in the initial search was the medical management of rheumatoid arthritis.
Key words used included arthroscopy, total shoulder replacement, hemiarthroplasty, reverse shoulder replacement, reverse, polarity shoulder replacement, resurfacing shoulder replacement, steroid injection, supra-scapular nerve blocks, pain killers, NSAIDS, physiotherapy.
Selection of papers
Four hundred and eleven papers were identified on initial search, with 160 remaining after de-duplication. Fifty-six papers were excluded after being deemed not relevant, with a further 61 excluded as a result of an incorrect study design. Following initial review, 43 papers remained. The abstracts of these papers were independently assessed by two authors to assess their relevance and suitability for inclusion in the review. A third author acted as a referee in case of any disagreement. There was perfect agreement between the two authors in the selection of studies to be included. Sixteen papers were selected and full texts retrieved. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Twenty-seven papers were excluded. Papers were excluded if they did not include patients with primary osteoarthritis of the shoulder or if they did not report clinical outcomes.
The selected studies were analyzed by the same two authors and key information was charted as shown in Table 1 .
Quality assessment
The quality of the selected articles was assessed by two authors (DB and ATK) using one of three tools:
1. AMSTAR measurement tool to assess systematic reviews.
CONSORT 'Consolidated Standards of Reporting
Trials' tool for RCTs.
TREND 'Transparent Reporting of Evaluations
with Non randomised Designs' tool for nonrandomized trials.
Systematic reviews all scored well when assessed according to the AMSTAR checklist. The main omissions were failing to list all excluded studies and to assess publication bias. RCTs again scored well against the CONSORT checklist. Common shortcomings were recruitment periods not being defined and reasons for participant losses not being made clear. Observational studies all scored well against TREND criteria. The level of agreement between both assessors was good, with a kappa value of 0.87.
Results

TSA and hemiarthroplasty
Function and pain outcome. Functional outcome was found to be significantly better for TSA over hemiarthroplasty in four studies. 6, 7, 8, 10 Outcome measures that reached significance reported by the studies were: patient satisfaction, range of motion (ROM), University of California Los Angeles (UCLA) shoulder score, American Shoulder and Elbow Surgeons (ASES) score and Constant score. Two studies, however, reported no significant functional advantage between the two treatment modalities. 9, 13 One study, however, was limited to 42 patients, reporting no significant difference in Western Ontario Osteoarthritis of the Shoulder (WOOS) score, Constant score, and UCLA and ASES scores at 2 years. 9 TSA was shown to result in significantly improved pain scores in three studies, 7, 8, 13 with three others finding no significant difference. 6, 9, 10 Revision. One systematic review reported 81% survival of TSAs at 20 years. 12 The study included TSA performed for a number of diagnoses; thus, it is difficult to extract data pertaining solely to TSA performed for osteoarthritis. It is not possible, from the study, to define risk factors for the osteoarthritis group alone; however, it was generally found that male sex, underlying rotator cuff disease and tumour were associated with an increased risk of revision. Body mass index (BMI) and co-morbidity were not found to increase revision risk. In a further systematic review, 7 revision rates were reported to be 10.2% for hemiarthroplasties compared to 6.5% for TSA. Some 8.1% of hemiarthroplasties required conversion to TSA as a result of pain, suggesting the glenoid progressively erodes over time, resulting in worsening outcomes. In TSA, the type of glenoid component employed appeared to have an impact on revision rates, with 6.8% of TSAs with metal backed glenoids requiring revision compared to 1.7% of TSAs with polyethylene glenoids. A Cochrane Collaboration review 10 reported greater revision rates for hemiarthroplasty based on two studies, although significance was not reached. An RCT 11 comparing cemented and uncemented humeral components reported glenoid loosening in four patients, three periprosthetic fractures and one TSA revision within 2 years of index procedure.
Cemented versus uncemented. A level one RCT 11 that compared cemented and uncemented humeral components in TSA found a significant improvement in WOOS score for the cemented group, which was more pronounced in males. No significant difference in ROM and strength was detected between the two groups.
Glenoid components in TSA. One RCT 14 evaluated 25 patients comparing the stability of cemented, all-polyethylene, keeled versus pegged glenoid components. They found no significant difference in the stability of either during the 2-year study period. Both components were found to have an average translation of less than 1 mm. Clinical outcomes were evaluated using the Constant score, which showed improvement across the board. No significant difference in clinical outcome was found between the two types of glenoid components.
Concomitant biceps tenodesis in shoulder arthroplasty
One study 15 compared TSAs and hemiarthroplasties undergoing concomitant biceps tenodesis against those that did not. Six hundred and eighty-eight shoulders (99 hemiarthroplasties and 589 TSAs) were included in which 121 underwent biceps tenodesis at arthroplasty. The improvement in outcome measures was found to be even greater in the group receiving tenodesis, except for pain scores, which did not show significant difference. Subjectively, patients also described better results if a concomitant biceps tenodesis was performed. There was no statistical difference in the complication rate between the groups. The study indicates that biceps tenodesis can improve results of shoulder arthroplasty; however, despite the positive results, several limitations exist. The surgical technique was not fully standardized, the condition of the biceps tendon was not recorded and a significant difference in patient mean age was noted. Average follow-up for the nontenodesis group was significantly longer than that of the tenodesis group; therefore, it may be that the superior results found in the group receiving tenodesis will be lost over time.
Biological glenoid resurfacing
Namdari et al. 16 performed a systematic review of seven case series (180 patients) to critically examine the outcomes of biological glenoid resurfacing in the treatment of glenohumeral arthritis. Pre-operative indications for resurfacing were not limited to primary osteoarthritis. Patients were followed up for a mean of 46.6 months. The outcome measures reported were multiple with no uniformity amongst studies. Statistically significant improvements were found in most outcome measures evaluated postoperatively, which indicated resurfacing can be successful in the short term; however, little evidence exists for any long-term results. The overall complication rate was 13.3% and the re-operation rate was 26%, which is higher than the reported values for other treatment options.
Reverse shoulder arthroplasty
Smith et al. 17 conducted a systematic review of 22 articles to evaluate the functional outcomes of RSA. Three of the included articles evaluated the use of RSR in arthropathy with associated cuff tear. The results showed that, after a minimum follow-up of between 8 and 24 months, the majority of patients will regain a functional reach and achieve better pain control, although rotation can remain problematic. Survival of the prosthesis at 10 years was reported to be 89%; however, the Constant score gradually declined with time and, when taken into account, survival fell to 79%. Complications associated with RSA for arthropathy with a cuff tear included dislocation (2% to 2.8%), infection (0% to 4%), glenoid loosening (0% to 4%), acromial fractures (1.4% to 4%), nerve palsy (0% to 1.4%) and scapular notching (49% to 70%). A further study 18 evaluated 19 RSAs and 23 TSAs for postoperative nerve injury. The incidence of peripheral neurological lesions was found to be significantly more common in the RSA group, with a 10.9-fold higher risk than the TSA group. Out of nine RSAs with a postoperative neurological deficit, eight resolved within 6 months. Mean arm lengthening after RSA of 2.7 AE 1.8 cm is suggested as a possible cause of the increased risk of neurological complications. There is limited evidence showing short-term benefit with use of RSA in arthropathy with cuff tear in older patients with low demands.
Autologous platelet preparations
One RCT 19 examined the effect of autologous platelet gel (APG) and activated platelet-poor plasma (PPP) treatment on 38 TSA patients postoperatively. The results of the study showed that APG and PPP therapy did not significantly influence retained postoperative haemoglobin and volume of auto-transfused blood. However, the therapy was shown to significantly improve postoperative pain scores and internal rotation in the treatment group.
Acupuncture
Lathia et al. 20 conducted a single-blind randomized study of 31 patients to evaluate whether acupuncture was effective in treatment of chronic shoulder pain. The patients were allocated randomly to three groups: two treatment groups with different methods of acupuncture and one control group where 'sham' nonpuncturing acupuncture needles were used. The groups consisted of patients over 18 years of age with shoulder pain for at least 8 weeks duration and with a Shoulder Pain and Disability Index (SPADI) score of 30 or more. The shoulder pathology was nonspecific and included a range of pathologies. The results of this study showed that, after 6 weeks of treatment, all three groups experienced clinical improvement demonstrated by a lower SPADI score, although this was only clinically significant in the acupuncture groups. The study is, however, not specific to osteoarthritis of the shoulder and the results cannot be extrapolated to recommend the use of acupuncture in shoulder arthritis.
Manipulative therapy
One systematic review 21 was found that investigated the effect of manual and manipulative therapy (MMT) for common shoulder pain and disorders. A myriad of shoulder pathologies were included, such as osteoarthritis, rotator cuff injuries, adhesive capsulitis, soft tissue disorders, neurogenic shoulder pain, shoulder pain secondary to cervical/thoracic and adjacent rib dysfunction. None of the included studies focused solely on osteoarthritis and the number of patients was very small, hence the benefit of MMT for osteoarthritis is impossible to extrapolate.
Discussion
This scoping review assessed the quality and content of recent published evidence over the last decade regarding the treatment of shoulder arthritis. The studies identified were unable to provide a clear indication of the best treatment for shoulder arthritis. The inclusion of a range of shoulder pathologies in some studies and the diversity in outcome measures used made it difficult for systematic reviews to effectively pool data. There is a need for standardization of outcome assessment following treatment of shoulder arthritis to enable meaningful comparisons in the future. There is generally a pressing need for good quality randomized trials to investigate the effectiveness of nonsurgical interventions, as well the need for a comparison of nonsurgical versus surgical interventions to determine the superiority of one intervention over the other. Most of the reviewed literature focuses on surgical interventions and the debate about TSA versus hemiarthroplasty. The systematic reviews of TSA versus hemiarthroplasty were of good quality, although the primary studies included in these reviews were generally of limited quality and had weaknesses. Better outcomes have been shown with TSA over hemiarthroplasty for shoulder osteoarthritis. This needs to be interpreted with caution in light of the limitations identified in these reviews. Regarding other operative interventions, there is limited evidence of insufficient quality to suggest that RSA is effective in relieving pain and improving function in the management of arthropathy with cuff tear. There is also insufficient evidence to recommend biological glenoid resurfacing or arthroscopic debridement.
Sparse evidence is available for all other interventions, whether it be operative or non-operative. The quality of evidence for nonsurgical management of shoulder arthritis remains limited. The majority of non-operative interventions address shoulder pain in its entirety and do not focus on osteoarthritis alone. Evidence for interventions such as physiotherapy and intra-articular corticosteroid injections is poor.
One of the current debates is whether better outcomes with TSA over hemiarthroplasty for shoulder osteoarthritis in the short and medium term will be offset be higher revision rates for TSA in the long term. The literature suggests that, in the short/medium term, the revision rate of glenoid components after TSA is significantly less than that of conversion from hemiarthroplasty to TSA as a result of poor outcomes such as progressive pain. We found little to document the long-term revision rates of TSA. Most studies performed consist of a small number of patients with relatively short follow-up, making it difficult to identify any risk factors for revision. The literature suggests that males are more likely to undergo revision surgery and that co-morbidities such as BMI confer no statistically significant increased risk of earlier revision.
The present review highlights the need for standardization of outcome assessment following the treatment of shoulder arthritis. The introduction of the collection patient-reported outcome measure (PROMS) for upper limb arthroplasty would be a potential way of achieving this. There is need to obtain good quality primary evidence for the common interventions used in the treatment of shoulder arthritis. Determining the effectiveness of nonsurgical treatments, the optimal timing of surgical intervention and the effectiveness of surgical interventions would be best achieved by conducting large, multicentre randomized clinical trials. Comparative studies of newer technologies such as resurfacing arthroplasty and stemless shoulder arthroplasty to establish their effectiveness are essential, and should be one of the areas of focus for future clinical trials. 46 
